Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Translational Internal Medicine

4 Issues per year

Open Access
Online
ISSN
2224-4018
See all formats and pricing
More options …

Systemic use of corticosteroids in neurological disorders

Miguel D’haeseleer
  • Corresponding author
  • Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels,
  • National Multiple Sclerosis Center, Melsbroek, Belgium
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2015-04-24 | DOI: https://doi.org/10.4103/2224-4018.135603

Abstract

Corticosteroids have been used for almost 60 years in medicine and their roles in patients have always been discussed by researchers and clinicians dedicated in the related field. Now they are still used in treatment of patients with neurological disorders. Usually Corticosteroids are used to decrease inflammations. In this review, we present five key indications, i.e., bacterial meningitis, myasthenia gravis, Bell’s palsy and giant cell (temporal) arteritis for the systemic use of corticosteroids in neurology based on a mix of prevalence, quality of evidence and impact on disease management.

Keywords: corticosteroids; systemic use; neurological disorders; prednisone

References

  • 1. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 2006;66:1696-702.Google Scholar

  • 2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.Google Scholar

  • 3. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;4:CD001331.Google Scholar

  • 4. Burton JM, O’Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012;12:CD006921.Google Scholar

  • 5. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-8.Google Scholar

  • 6. Bhatt SM, Lauretano A, Cabellos C, Halpin C, Levine RA, Xu WZ, et al. Progression of hearing loss in experimental pneumococcal meningitis: Correlation with cerebrospinal fluid cytochemistry. J Infect Dis 1993;167:675-83.Google Scholar

  • 7. Sáez-Llorens X, Jafari HS, Severien C, Parras F, Olsen KD, Hansen EJ, et al. Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonalantibodies and dexamethasone in experimental Haemophilus meningitis. J Clin Invest 1991;88:2003-11.Google Scholar

  • 8. de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56.Google Scholar

  • 9. Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007;357:2441-50.Web of ScienceGoogle Scholar

  • 10. Nguyen TH, Tran TH, Thwaites G, Ly VC, Dinh XS, Ho Dang TN, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007;357:2431-40.Web of ScienceGoogle Scholar

  • 11. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013;6:CD004405.Google Scholar

  • 12. Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976;26:729-40.Google Scholar

  • 13. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann Neurol 1984;15:291-8.Google Scholar

  • 14. Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986;36:729-32.Google Scholar

  • 15. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974;290:81-4.Google Scholar

  • 16. Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med 2007;357:1598-607.Web of ScienceGoogle Scholar

  • 17. Engström M, Berg T, Stjernquist-Desatnik A, Axelsson S, Pitkäranta A, Hultcrantz M, et al. Prednisolone and valaciclovir in Bell’s palsy: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008;7:993-1000. Web of ScienceGoogle Scholar

About the article

Published Online: 2015-04-24

Published in Print: 2014-06-01


Citation Information: Journal of Translational Internal Medicine, Volume 2, Issue 2, Pages 70–72, ISSN (Online) 2224-4018, DOI: https://doi.org/10.4103/2224-4018.135603.

Export Citation

© 2015. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in